Evidence map›Paper›PMID 33968342›Full record

ArticleGastroenterology and hepatology from bed to bench2021

Tenofovir in the treatment of hepatitis B virus infection after liver transplantation, a single center large population study.

Fardad Ejtehadi, Mohammad Reza Pashaei, Alireza Shamsaeefar, Nasrin Motazedian, Gholam Reza Sivandzadeh, Ramin Niknam, Seyed Ali Malekhosseini, Kamran B Lankarni

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in Gastroenterology and hepatology from bed to bench, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
0.2field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 1 citations in OpenAlex.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Fardad EjtehadiGastroenterohepatology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Mohammad Reza PashaeiDepartment of Gastroenterology, Urmia University of Medical Sciences, Urmia, Iran.
Alireza ShamsaeefarShiraz Organ Transplant Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Nasrin MotazedianShiraz Transplant Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Gholam Reza SivandzadehGastroenterohepatology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Ramin NiknamGastroenterohepatology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Seyed Ali MalekhosseiniShiraz Organ Transplant Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Kamran B LankarniHealth Policy Research Center, Institute of Health, Shiraz University of Medical Sciences, Shiraz, Iran.
Shiraz University of Medical Sciences · IRUrmia University of Medical Sciences

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimThis study investigated the safety and efficacy of tenofovir disoproxil fumarate (TDF) compared with lamivudine (LAM) in the prevention of recurrent HBV infection after liver transplantation (LT).

backgroundAlthough the recurrence of hepatitis B virus after liver transplantation (LT) is now very uncommon with both nucleoside and nucleotide analogs represented with lamivudine and tenofovir disoproxil fumarate, respectively, few studies have compared the two classes.

methodsA total of 302 HBV-related post-transplant patients who received liver transplants from deceased donors were enrolled in this retrospective study from 2011 to 2015 in the Shiraz Organ Transplant Center, Iran. The demographic data, kidney function, recurrence, resistance rate, and acute rejections at 1-, 6-, and 12-month intervals and after 12 months were compared on TDF (n=209) and lamivudine (n=93) groups.

resultsDuring a median follow-up period of 42.9 months, mean creatinine level was not significantly different between the two groups. Hepatitis B virus recurrence rate as well as acute graft rejection episode had no statistical difference in either group over the study period.

conclusionKidney function, creatinine level, disease recurrence, and acute graft rejection were comparable between tenofovir disoproxil fumarate and lamivudine in patients who received follow-up periods.

Indexed as

Hepatitis BLiver transplantationTherapeutics

Identifiers

PMID33968342
PMCPMC8101521
OpenAlexW3162122886

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.